EUR 7.17
(-1.38%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 59.07 Million EUR | -0.07% |
2022 | 59.12 Million EUR | 9.52% |
2021 | 53.98 Million EUR | 51.61% |
2020 | 35.6 Million EUR | 17.15% |
2019 | 30.39 Million EUR | 100.65% |
2018 | 15.14 Million EUR | -30.85% |
2017 | 21.9 Million EUR | -12.45% |
2016 | 25.02 Million EUR | 893.33% |
2015 | 2.51 Million EUR | -9.49% |
2014 | 2.78 Million EUR | 131.92% |
2013 | 1.2 Million EUR | 31.15% |
2012 | 915 Thousand EUR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 59.47 Million EUR | 0.0% |
2023 FY | 59.07 Million EUR | -0.07% |
2023 Q2 | 57.86 Million EUR | 0.0% |
2023 Q4 | 59.07 Million EUR | 0.0% |
2022 FY | 59.12 Million EUR | 9.52% |
2022 Q4 | 59.12 Million EUR | 0.0% |
2022 Q2 | 55.46 Million EUR | 0.0% |
2021 FY | 53.98 Million EUR | 51.61% |
2021 Q4 | 53.98 Million EUR | 0.0% |
2021 Q2 | 45.9 Million EUR | 0.0% |
2020 Q4 | 35.6 Million EUR | 0.0% |
2020 FY | 35.6 Million EUR | 17.15% |
2020 Q2 | 34.32 Million EUR | 0.0% |
2019 FY | 30.39 Million EUR | 100.65% |
2019 Q4 | 30.39 Million EUR | 0.0% |
2019 Q2 | 32.18 Million EUR | 0.0% |
2018 FY | 15.14 Million EUR | -30.85% |
2018 Q4 | 15.14 Million EUR | 0.0% |
2018 Q2 | 19.85 Million EUR | 0.0% |
2017 FY | 21.9 Million EUR | -12.45% |
2017 Q2 | 20.8 Million EUR | 0.0% |
2017 Q4 | 21.9 Million EUR | 0.0% |
2016 Q2 | 14.7 Million EUR | 0.0% |
2016 FY | 25.02 Million EUR | 893.33% |
2016 Q4 | 25.02 Million EUR | 0.0% |
2015 FY | 2.51 Million EUR | -9.49% |
2015 Q2 | 2.6 Million EUR | 0.0% |
2015 Q4 | 2.51 Million EUR | 0.0% |
2014 FY | 2.78 Million EUR | 131.92% |
2014 Q4 | 2.78 Million EUR | 0.0% |
2014 Q2 | 1.38 Million EUR | 0.0% |
2013 Q1 | - EUR | 0.0% |
2013 Q3 | 1.2 Million EUR | 0.0% |
2013 Q4 | 1.2 Million EUR | 0.0% |
2013 FY | 1.2 Million EUR | 31.15% |
2012 FY | 915 Thousand EUR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
ABIONYX Pharma SA | 6.91 Million EUR | -754.731% |
ABIVAX Société Anonyme | 131.05 Million EUR | 54.919% |
Adocia SA | 31.87 Million EUR | -85.375% |
Aelis Farma SA | 13.08 Million EUR | -351.674% |
Biophytis S.A. | 15.84 Million EUR | -272.762% |
Advicenne S.A. | 24.37 Million EUR | -142.355% |
genOway Société anonyme | 14.45 Million EUR | -308.582% |
IntegraGen SA | 5.97 Million EUR | -887.977% |
Medesis Pharma S.A. | 6.42 Million EUR | -819.348% |
Neovacs S.A. | 3.71 Million EUR | -1491.515% |
NFL Biosciences SA | 3.62 Million EUR | -1531.709% |
Plant Advanced Technologies SA | 6.78 Million EUR | -771.07% |
Quantum Genomics Société Anonyme | 3.31 Million EUR | -1684.806% |
Sensorion SA | 13.22 Million EUR | -346.645% |
Theranexus Société Anonyme | 5.01 Million EUR | -1077.767% |
TME Pharma N.V. | 2.78 Million EUR | -2021.329% |
Valbiotis SA | 13.7 Million EUR | -330.982% |
TheraVet SA | 1.48 Million EUR | -3878.403% |
Valerio Therapeutics Société anonyme | 20.46 Million EUR | -188.641% |
argenx SE | 402.79 Million EUR | 85.333% |
BioSenic S.A. | 32.26 Million EUR | -83.111% |
Celyad Oncology SA | 9.97 Million EUR | -492.093% |
DBV Technologies S.A. | 38.74 Million USD | -52.48% |
Galapagos NV | 1.56 Billion EUR | 96.217% |
Genfit S.A. | 105.92 Million EUR | 44.224% |
GeNeuro SA | 20.13 Million EUR | -193.343% |
Hyloris Pharmaceuticals SA | 8.61 Million EUR | -586.008% |
Innate Pharma S.A. | 132.29 Million EUR | 55.342% |
Inventiva S.A. | 101.59 Million EUR | 41.847% |
MaaT Pharma SA | 22.46 Million EUR | -162.982% |
MedinCell S.A. | 77.77 Million EUR | 24.034% |
Nanobiotix S.A. | 95.74 Million EUR | 38.292% |
Onward Medical N.V. | 25.69 Million EUR | -129.897% |
Oryzon Genomics S.A. | 25.12 Million EUR | -135.136% |
Oxurion NV | 19.73 Million EUR | -199.346% |
Pharming Group N.V. | 228.28 Million EUR | 74.121% |
Poxel S.A. | 53.9 Million EUR | -9.607% |
GenSight Biologics S.A. | 34.72 Million EUR | -70.124% |
Transgene SA | 26.51 Million EUR | -122.797% |
Financière de Tubize SA | 123.65 Million EUR | 52.221% |
UCB SA | 6.56 Billion EUR | 99.1% |
Valneva SE | 341.14 Million EUR | 82.682% |
Vivoryon Therapeutics N.V. | 4.54 Million EUR | -1199.296% |